Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T20:12:24.838Z.
Calculation as of: 2026-10-06T20:12:24.838Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e1439c3a9e54fb1f97ae208c5489c534aa692153c8f3b45d8dac24981f451ae3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$22.00M
EV/FCF Ratio
4.24x
TTM Avg
11.24x
3Y Avg
10.04x
5Y Avg
10.04x
Market Cap
$23.38M
EV/FCF Ratio
6.33x
TTM Avg
10.18x
3Y Avg
8.39x
5Y Avg
7.37x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LeonaBio, Inc. (LONA) | $22.68M | N/A | N/A | N/A | N/A |
| Rein Therapeutics Inc. (RNTX)vs › | $23.06M | N/A | N/A | N/A | N/A |
| Modular Medical, Inc. (MODD)vs › | $22.25M | N/A | N/A | N/A | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.00M | 4.24x | 11.24x | 10.04x | 10.04x |
| TherapeuticsMD, Inc. (TXMD)vs › | $23.38M | 6.33x | 10.18x | 8.39x | 7.37x |
| Kyntra Bio, Inc. (KYNB)vs › | $24.13M | N/A | 104.27x | 104.96x | 131.27x |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.44M | N/A | N/A | N/A | N/A |
| NextCure, Inc. (NXTC)vs › | $20.84M | N/A | 232.26x | 232.26x | 232.26x |
| InspireMD, Inc. (NSPR)vs › | $24.69M | N/A | N/A | N/A | N/A |
| ABVC BioPharma, Inc. (ABVC)vs › | $25.22M | N/A | 248.89x | 248.89x | 248.89x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
